Guardant Health 8-K Signals Upcoming Financial Disclosure

TL;DR

**Guardant Health just filed an 8-K, signaling upcoming financial results and disclosures.**

AI Summary

Guardant Health, Inc. filed an 8-K on January 8, 2024, indicating that it will be disclosing information related to its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This filing signals that the company is likely to release important financial updates, potentially including preliminary earnings or operational metrics, which could impact investor perception of its current performance and future outlook. Investors should pay close attention to any subsequent announcements from Guardant Health, Inc. as these disclosures could significantly influence the stock's price.

Why It Matters

This filing alerts investors that Guardant Health is preparing to release significant financial information, which could reveal the company's recent performance and future prospects, directly affecting its stock valuation.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the upcoming financial disclosures it signals carry inherent market risk depending on the content.

Analyst Insight

A smart investor would monitor Guardant Health's news channels closely for the actual financial disclosures that this 8-K foreshadows, as those will contain the actionable information regarding the company's performance.

Key Players & Entities

• Guardant Health, Inc. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for Guardant Health, Inc.
• 001-38683 (dollar_amount) — Commission File Number
• 45-4139254 (dollar_amount) — IRS Employer Identification No.
• 3100 Hanover Street, Palo Alto, California 94304 (company) — address of principal executive offices
• 855-698-8887 (dollar_amount) — registrant's telephone number
• GH (company) — trading symbol for Guardant Health, Inc.
• The Nasdaq Global Select Market (company) — exchange where Guardant Health, Inc. common stock is registered

FAQ

From the Filing

0001193125-24-004446.txt : 20240108 0001193125-24-004446.hdr.sgml : 20240108 20240108161733 ACCESSION NUMBER: 0001193125-24-004446 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 24520363 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 d710991d8k.htm 8-K 8-K false 0001576280 0001576280 2024-01-08 2024-01-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024     GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38683   45-4139254 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (IRS Employer Identification No.) 3100 Hanover Street Palo Alto , California 94304 (Address of principal executive offices) (Zip Code) 855 - 698-8887 (Registrant’s telephone number, include area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 2.02. Results of Operations and Financial Conditions. On January 8, 2024, Guardant Health, Inc. (the “Company”) announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.   Item 7.01. Regulation FD Disclosure. The Company will post the presentation that it will present at the 2024 J.P. Morgan Healthcare Conference on January 8, 2024 to the Company’s website, www.guardanthealth.com, on the “Events & Presentations” page under the “In